BPC-157: The Complete Research Guide to Body Protection Compound
Last updated: · Monthly refresh · Updated on regulatory changes
100+
Published studies
15
Amino acids (gastric pentadecapeptide)
N/A
Not FDA-approved (research compound)
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Medical disclaimer: This guide is for educational purposes only and is not medical advice. BPC-157 is a research compound not approved by the FDA for any medical use. Always consult a qualified healthcare provider before starting any peptide protocol. See our full medical disclaimer.
In this guide
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is a synthetic peptide consisting of 15 amino acids, which makes it a pentadecapeptide. The sequence is derived from a larger protein called BPC (Body Protection Compound) that is naturally found in human gastric juice.
The "gastric" origin is the key to understanding BPC-157. Unlike most peptides used in research, BPC-157 is stable in gastric acid. That stability is unusual and is why it can be administered orally, not just by injection. Most peptides degrade in the stomach within minutes.
BPC-157 works through multiple biological mechanisms simultaneously. The three most studied are:
- Angiogenesis: Promotes the formation of new blood vessels, which is critical for tissue repair. Injured tissue needs blood supply to heal. BPC-157 upregulates VEGF (vascular endothelial growth factor) expression in damaged areas.
- Growth factor expression: Increases expression of multiple growth factors including EGF (epidermal growth factor) and FGF (fibroblast growth factor). These proteins drive cell proliferation and tissue regeneration.
- Nitric oxide system modulation: Interacts with the nitric oxide (NO) system, which regulates blood flow, inflammation, and immune response. This interaction appears to be central to many of BPC-157's observed effects in animal studies.
Over 100 studies have been published on BPC-157 since the 1990s, primarily from the research group of Predrag Sikiric at the University of Zagreb. The vast majority of this research is preclinical: animal models (primarily rats) and in vitro (cell culture) studies. There are no completed, published human clinical trials as of March 2026.
That distinction matters. The animal data is extensive and consistently positive across dozens of injury and disease models. But animal results do not automatically translate to humans. The lack of human trials is the single biggest gap in the BPC-157 evidence base.
For full compound data, mechanism details, and pharmacokinetics, see the BPC-157 compound profile.
Research-backed benefits
The published research on BPC-157 spans an unusually wide range of tissue types and injury models. Below is a summary of the major research areas, with evidence strength rated based on the volume and consistency of published preclinical data.
| Research Area | Key Findings | Evidence Strength |
|---|---|---|
| Tendon and ligament repair | Accelerated healing in Achilles tendon, MCL, and rotator cuff models | Strong (multiple animal studies) |
| Gut healing | Protection against NSAID-induced lesions, alcohol damage, IBD models | Strong (extensive animal data) |
| Muscle recovery | Improved healing in crushed and transected muscle models | Moderate (consistent but fewer studies) |
| Neuroprotection | Reduced brain damage in traumatic injury models, nerve regeneration | Moderate (emerging data) |
| Anti-inflammatory | Reduced inflammation markers across multiple injury types | Moderate (consistent secondary finding) |
Important context: "strong evidence" here means strong within preclinical research. It does not mean the same thing as strong clinical evidence from human trials. Even the best-studied BPC-157 benefits lack the randomized controlled human trial data that FDA approval requires.
For a detailed breakdown of each research area, see BPC-157 benefits: what the research actually shows.
BPC-157 for gut health
Gut healing is arguably BPC-157's most well-documented application. This makes sense given its origin: the peptide is derived from a protein naturally present in gastric juice, and it is stable in stomach acid. The gut is its native environment.
The published research shows protective and healing effects across multiple gut injury models:
- Gastric ulcers: BPC-157 accelerated healing in multiple animal ulcer models, including those induced by NSAIDs, alcohol, and stress.
- Inflammatory bowel disease: Animal IBD models showed reduced inflammation, improved mucosal integrity, and accelerated tissue repair.
- NSAID-induced gut damage: Particularly relevant because NSAID use is widespread. BPC-157 showed protective effects against the gastric and intestinal lesions that NSAIDs commonly cause.
- Intestinal anastomosis: Improved healing at surgical connection sites in animal models, suggesting applications in post-surgical recovery.
The mechanism appears to involve both direct cytoprotection (protecting cells from damage) and enhanced repair through angiogenesis and growth factor expression. The nitric oxide system interaction is particularly relevant in the gut, where NO plays a central role in mucosal defense.
Community interest in BPC-157 for gut health has surged alongside the rise of GLP-1 medications, which commonly cause GI side effects. Many users report combining BPC-157 with semaglutide or tirzepatide specifically for gut protection. That use case is covered in the next section.
Get the Peptide Starter Kit (free)
A quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
BPC-157 + semaglutide stack
The most common reason people combine BPC-157 with semaglutide (Ozempic, Wegovy) is GI protection. Nausea, diarrhea, and constipation are the most frequently reported side effects of GLP-1 medications. BPC-157's gut-protective properties in animal research make it a logical candidate for mitigating those effects.
This is a community-driven protocol, not a clinically studied combination. No published research has examined the interaction between BPC-157 and semaglutide. The rationale is based on extrapolating BPC-157's gastric protection data to the GI side effects of GLP-1 drugs. That extrapolation is reasonable but unproven.
Community reports generally describe:
- Reduced nausea during semaglutide dose escalation
- Improved gut comfort throughout treatment
- Faster resolution of GI side effects
These are anecdotal reports, not controlled data. Anyone considering this combination should discuss it with a healthcare provider who understands both compounds and can monitor for potential interactions.
For the full analysis: BPC-157 and semaglutide together: what you need to know. For the tirzepatide combination: tirzepatide + BPC-157 stack.
BPC-157 vs TB-500
BPC-157 and TB-500 (thymosin beta-4) are the two most commonly discussed healing peptides. They work through fundamentally different mechanisms, which is why they are frequently stacked together rather than treated as either/or alternatives.
| Factor | BPC-157 | TB-500 |
|---|---|---|
| Primary mechanism | Angiogenesis, growth factors, NO system | Actin regulation, cell migration |
| Action type | Primarily local (targeted to injury site) | Primarily systemic (whole-body) |
| Best for | Tendon/ligament, gut healing, localized injuries | Systemic inflammation, cardiac repair, general recovery |
| Oral availability | Yes (gastric acid stable) | No (injection only) |
| Stacking | Commonly stacked together for comprehensive recovery protocols | |
The general community consensus: BPC-157 for targeted, local healing (especially gut and specific tendons or ligaments). TB-500 for systemic anti-inflammatory effects and broader recovery support. Both together for comprehensive healing protocols, particularly for athletes or people recovering from surgery.
Detailed comparison: BPC-157 vs TB-500 comparison. Editorial analysis: BPC-157 vs TB-500: which healing peptide is better?. Stack guide: healing stack: BPC-157 + TB-500.
Legal status and FDA
The regulatory status of BPC-157 in the United States is evolving and uncertain in 2026. Here is the current situation:
- Not a controlled substance: BPC-157 is not listed as a Schedule I-V controlled substance by the DEA.
- Not FDA-approved: BPC-157 has no FDA approval for any medical indication. No IND (Investigational New Drug) application has led to completed human trials.
- Compounding pharmacy access: BPC-157 has been available through compounding pharmacies. However, the FDA has increased scrutiny of compounded peptides in 2025-2026, and availability through this channel may be restricted.
- Research chemical status: Available for purchase as a research chemical from various vendors. Quality and purity vary significantly between suppliers.
The 2026 regulatory landscape is particularly important. The FDA has signaled increased enforcement around peptides sold through compounding pharmacies, and several compounds have been reclassified or restricted. BPC-157's status could change with relatively little advance notice.
For the full regulatory analysis: FDA peptide regulations in 2026. For RFK administration impact: RFK and peptide regulations in 2026. For the broader legal landscape: research peptide legal landscape in 2026.
Dosing protocols
BPC-157 dosing in community protocols typically follows these parameters. These are based on extrapolation from animal research and community experience, not from human clinical trials.
| Parameter | Typical Protocol |
|---|---|
| Dose range | 250-500 mcg per injection |
| Frequency | Twice daily (morning and evening) |
| Administration | Subcutaneous injection near injury site, or oral capsule |
| Protocol length | 4-8 weeks (some run shorter or longer depending on response) |
| Reconstitution | Bacteriostatic water, standard peptide reconstitution protocol |
Subcutaneous injection near the injury site is the most common administration method for musculoskeletal issues. For gut-related protocols, injection in the abdominal area or oral dosing is typical.
For reconstitution guidance: how to reconstitute peptides. For injection technique: peptide injection sites and rotation. For storage: how to store peptides properly. For dose calculations: peptide dosage calculator and reconstitution calculator.
Oral vs injectable
BPC-157 is one of the few peptides that can be taken orally with demonstrated activity. Its stability in gastric acid, derived from its gastric juice origin, allows it to survive the digestive environment that destroys most peptides.
That said, oral and injectable forms are not equivalent:
| Factor | Oral | Injectable (SubQ) |
|---|---|---|
| Bioavailability | Lower (first-pass metabolism) | Higher (bypasses digestive system) |
| Best for | Gut-specific healing, GI protection | Musculoskeletal injuries, systemic effects |
| Convenience | High (capsule, no preparation) | Low (reconstitution, sterile technique required) |
| Typical dose | 500 mcg 2x/day (higher to offset bioavailability) | 250-500 mcg 2x/day |
The practical decision usually comes down to the target. If the goal is gut healing or GI protection (including alongside GLP-1 medications), oral BPC-157 delivers the peptide directly to the tissue that needs it. If the goal is tendon, ligament, or muscle repair, subcutaneous injection near the injury site is generally preferred for higher local concentration.
Some protocols use both simultaneously: oral for gut protection and injectable for a specific injury.
Safety
The safety profile of BPC-157 in published research is notably clean. Across more than 100 animal studies spanning nearly three decades, no serious adverse events have been reported. No organ toxicity. No mutagenicity. No mortality attributed to the compound.
That is a strong signal for a preclinical compound, but it comes with a critical limitation: there are no published human clinical trials. Animal safety data does not guarantee human safety. Rare side effects, drug interactions, and long-term effects can only be identified through large-scale human studies.
Commonly reported effects in community use:
- Injection site reactions (redness, minor swelling, soreness) are the most common complaint
- Transient nausea or dizziness reported by some users
- Headache reported occasionally
- Fatigue reported rarely
What has not been reported: serious adverse events, hospitalizations, organ damage, or deaths attributed to BPC-157 in either published research or community reports. This does not mean serious effects cannot occur. It means they have not been observed in the relatively limited population that has used it.
Anyone using BPC-157 should do so under medical supervision. The compound is unregulated, and quality control varies dramatically between suppliers. Third-party testing certificates of analysis (COAs) are a minimum requirement for any research peptide purchase.
For comprehensive safety analysis: peptide therapy risks and how to mitigate them.
Stay current on BPC-157 research and regulation.
New studies, FDA updates, dosing protocols, and stacking guides. Delivered weekly. No spam. Unsubscribe anytime.
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
All BPC-157 content on this site
This hub aggregates every BPC-157 article, comparison, stack, and reference page on Peptide Nerds. Each article below also links back to this hub.
Core guides
- BPC-157 Benefits: What the Research Actually Shows
- BPC-157 for Gut Healing: IBS, Leaky Gut, and IBD
- BPC-157 Dosing Guide: Subcutaneous vs Oral Protocols
- TB-500 for Injury Recovery: Mechanism, Dosing, and What to Expect
- BPC-157 and Semaglutide Together: What You Need to Know
- BPC-157 vs TB-500: Which Healing Peptide Is Better?
- BPC-157 + TB-500 Stack for Recovery
Regulatory and legal
- FDA Peptide Regulations in 2026
- RFK and Peptide Regulations in 2026
- Research Peptide Legal Landscape in 2026
Practical guides
- How to Reconstitute Peptides
- Peptide Injection Sites and Rotation
- How to Store Peptides Properly
- Peptide Therapy Risks and How to Mitigate Them
Comparisons
Stacks
- Healing Stack: BPC-157 + TB-500
- Gut Healing Stack: BPC-157 + KPV
- Joint and Tendon Stack: BPC-157 + TB-500 + GHK-Cu
- Tirzepatide + BPC-157 Stack
Tools
Related categories
Compound reference page
Frequently asked questions
What does BPC-157 do?
BPC-157 promotes tissue repair through multiple mechanisms including angiogenesis (new blood vessel formation), upregulation of growth factor expression (VEGF, EGF, FGF), and modulation of the nitric oxide system. Animal studies show accelerated healing in tendons, ligaments, muscles, and gut tissue. It is a 15-amino-acid peptide derived from a protein found in human gastric juice.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any medical use. It is classified as a research compound. There are no completed human clinical trials establishing safety or efficacy for any condition. All published research is preclinical (animal models and in vitro studies). The FDA has raised concerns about peptides sold through compounding pharmacies, and the regulatory landscape for BPC-157 is evolving in 2026.
Can you take BPC-157 orally?
Yes. BPC-157 is available in oral capsule form and has shown activity via oral administration in animal studies, which is unusual for peptides. However, oral bioavailability is lower than subcutaneous injection. Some users prefer oral dosing for gut-specific benefits and convenience, while others choose injection for systemic tissue repair. The optimal route depends on the target tissue and individual preference.
How long does BPC-157 take to work?
Most users in community reports describe noticeable effects within 1 to 2 weeks, particularly for pain reduction and improved mobility. Typical protocols run 4 to 8 weeks. The timeline varies significantly depending on the type and severity of injury, dosage, and administration route. Animal studies show measurable tissue repair markers within days, but translating animal timelines to humans is not straightforward.
Can you stack BPC-157 with semaglutide?
This is a common community protocol. The rationale is that BPC-157 may help protect the gut lining from GI side effects associated with GLP-1 medications like semaglutide. This combination has not been studied in clinical trials. Anyone considering stacking peptides should consult a qualified healthcare provider who understands both compounds.
What is better, BPC-157 or TB-500?
They work through different mechanisms and are often used for different purposes. BPC-157 acts primarily through local tissue repair, angiogenesis, and gut healing. TB-500 (thymosin beta-4) works systemically through actin regulation and broader anti-inflammatory pathways. BPC-157 is generally preferred for gut issues and localized injuries. TB-500 is preferred for systemic inflammation. Many protocols stack both for comprehensive recovery.
Is BPC-157 legal?
BPC-157 is currently available as a research compound in the United States. It is not a controlled substance. However, the regulatory status is evolving. In 2026, the FDA has increased scrutiny on peptides sold through compounding pharmacies, and some previously available compounds have been reclassified. Check current regulations in your jurisdiction before purchasing.
What are BPC-157 side effects?
Published animal research reports minimal adverse effects. The most commonly reported side effect in community use is mild injection site irritation (redness, swelling, or soreness). Some users report transient nausea, dizziness, or headache. No serious adverse events have been reported in published research. However, the lack of formal human clinical trials means the full side effect profile is not established.
Sources
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lesson from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 2018.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Orthopaedic Surgery and Research, 2011.
- Seiwerth S, et al. BPC 157's Effect on Healing. Current Pharmaceutical Design, 2018.
- Sikiric P, et al. The pharmacological properties of the novel peptide BPC 157 (PL-10). Current Pharmaceutical Design, 2014.
- Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Journal of Physiology and Pharmacology, 2010.
Get the Peptide Starter Kit (free)
A quick-start guide covering GLP-1 peptides, dosing basics, side effect management, and what to discuss with your doctor.
Medical disclaimer: The information on this page is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. BPC-157 is a research compound not approved by the FDA for any indication. Always consult a qualified healthcare provider before starting any peptide protocol. Individual results vary. See our full medical disclaimer.